bilaterals.org logo
bilaterals.org logo

medicines


EU-Mercosur trade agreement: A bad deal for transparency, policy coherence and access to medicines
Negotiations are now nearing completion and there are increasing concerns among public health advocates, patient and consumer organisations, and other stakeholders, both in Europe and the Americas.
South Centre statement on EU-MERCOSUR trade negotiations
EU-MERCOSUR trade negotiations must not impose TRIPS Plus provisions on protection and enforcement of intellectual property rights.
EU-Mercosur FTA puts at risk access to medicines in Brazil, new impact assessment study finds
The adoption of the measures proposed by the EU could put the sustainability of access to health policies in Brazil at risk, as they could sharply increase public expenditures on medicines.
Time for costly medicine monopolies to go from TPP trade talks
The latest plan to get the controversial trade deal up and running involves freezing some of its controversial rules, including rules for biologic drugs, an expensive class of medicines often used to treat conditions such as cancer and rheumatoid arthritis.
New paper explains TPP’s impact on access to medicines in member countries
As the TPP-11 meet to attempt to revive the TPP without the US, the research findings show how damaging the original medicine proposals would be.
India to oppose anti-generics proposals at RCEP meet
India firm in opposing proposals that could hinder global access to affordable generic drugs
India will not cross red lines on generic drugs in RCEP, but stay vigilant, say officials
Healthcare watchers are calling on India to resist RCEP
Access to affordable stents and other medical devices – Indian Government should reject the bullying tactics of the US based medical device industry
Access to health products is non-negotiable; the Indian Government should reject the bullying tactics of the US based medical device industry.
RCEP negotiations should not restrict global access to affordable medicines and vaccines
RCEP negotiations should not restrict global access to affordable medicines and vaccines
5 hidden costs of the RCEP to people and planet
The RCEP has hidden costs for people’s lives
RCEP: Robbing communities to extract profit
RCEP will give multinational corporations unprecedented rights
Free trade talks with EFTA grouping hit IPR, services wall
Switzerland insists on intellectual property commitments beyond TRIPS.
Sanofi Aventis Ukraine seeks to file claim to international court to protect investment in Ukraine
Sanofi Aventis Ukraine LLC, part of Sanofi global pharmaceutical company, seeks to file a claim against Ukraine to the International Investment Arbitration.
Foreign patent owners can challenge domestic judgments under international investment arbitration
The first ever final award on patents in international investment arbitration by ICSID in the case of Eli Lilly v. Canada has effectively cleared the way for raising future disputes by foreign IPR owners against domestic institutions which can result in stronger and robust IP protection regime.
Canada introduces patent term extensions for pharmaceutical patents
The new regime has been implemented in order to meet Canada’s obligations under the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union
TPP 11 Sydney meeting vindicates community concerns
TPP 11 negotiators have agreed to suspend controversial clauses on medicine monopolies and some governments want to renegotiate other clauses, vindicating public interest group concerns
Vietnam proposes amendments to stalled TPP trade deal at Sydney talks: sources
Officials from 11 of the 12 countries that committed to the Trans-Pacific Partnership (TPP) trade deal are meeting in Sydney for talks to re-energize the stalled agreement and discuss amendmends to the pact following the withdrawal of the US.
Health community’s concerns re TPP11 proposed next steps
Stronger intellectual property protection would benefit the US in return for no concessions, civil society groups tell TPP11 Ministers
Pharmaceutical prices, intellectual property rights emerge as key issues in KORUS FTA discussions
Through the KORUS revision, the US is openly seeking to bridge its trade deficit with Korea by renegotiating specific terms for individual product categories.
Neelam Deo on EU-India’s perplexing relationship: Trade, Europe’s hypocrisy and China concern
Former diplomat says the EU’s insistence on opening up on wine imports from France and automobile imports from Germany have held up the EU-India FTA negotiations.